Defining and Targeting Esophagogastric Cancer Genomic Subsets With Patient-Derived Xenografts
暂无分享,去创建一个
N. Schultz | Laura H. Tang | D. Solit | W. Chatila | D. Coit | Y. Janjigian | J. Hechtman | R. H. Moy | E. de Stanchina | M. Mattar | V. Strong | D. Molena | Walid K. Chatila | S. Maron | H. Walch | David R. Jones
[1] E. Van Cutsem,et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (G/GEJ) cancer: Initial findings of the global phase 3 KEYNOTE-811 study. , 2021, Journal of Clinical Oncology.
[2] F. Lordick,et al. Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm , 2021, Nature Reviews Clinical Oncology.
[3] A. Jemal,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.
[4] Leah M Chase,et al. Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): a phase 2 study evaluating an individualized treatment strategy for metastatic disease. , 2020, Cancer discovery.
[5] S. Wong,et al. Evaluation of molecular subtypes and clonal selection during establishment of patient-derived tumor xenografts from gastric adenocarcinoma , 2020, Communications Biology.
[6] Y. Bang,et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. , 2020, The New England journal of medicine.
[7] B. Taylor,et al. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. , 2020, The Lancet. Oncology.
[8] A. Bass,et al. A comprehensive PDX gastric cancer collection captures cancer cell intrinsic transcriptional MSI traits. , 2019, Cancer research.
[9] N. Gotoh,et al. Patient-Derived Xenograft Models of Breast Cancer and Their Application , 2019, Cells.
[10] B. Taylor,et al. EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer. , 2018, Cancer discovery.
[11] Mehmet Toner,et al. Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts. , 2018, Cancer discovery.
[12] Andrea Sottoriva,et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers , 2018, Science.
[13] Marissa Mattar,et al. Establishing and Maintaining an Extensive Library of Patient-Derived Xenograft Models , 2018, Front. Oncol..
[14] Leah M Chase,et al. Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for EGFR-Amplified Gastroesophageal Adenocarcinoma. , 2018, Cancer discovery.
[15] D. Cunningham,et al. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2017, The Lancet. Oncology.
[16] M. Hidalgo,et al. Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] K. Lillemoe,et al. Tumor engraftment in patient-derived xenografts of pancreatic ductal adenocarcinoma is associated with adverse clinicopathological features and poor survival , 2017, PloS one.
[18] Moriah H Nissan,et al. OncoKB: A Precision Oncology Knowledge Base. , 2017, JCO precision oncology.
[19] M. Shah,et al. Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial , 2017, JAMA oncology.
[20] Donavan T. Cheng,et al. Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients , 2017, Nature Medicine.
[21] Benjamin J. Raphael,et al. Integrated genomic characterization of oesophageal carcinoma , 2017, Nature.
[22] Yoon Young Choi,et al. Establishment and characterisation of patient-derived xenografts as paraclinical models for gastric cancer , 2016, Scientific Reports.
[23] M. Nowak,et al. Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers , 2015, Nature Communications.
[24] Jason G. Jin,et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes , 2015, Nature Medicine.
[25] J. Huh,et al. Correlation between tumor engraftment in patient-derived xenograft models and clinical outcomes in colorectal cancer patients , 2015, Oncotarget.
[26] Steven J. M. Jones,et al. Comprehensive molecular characterization of gastric adenocarcinoma , 2014, Nature.
[27] Manuel Hidalgo,et al. Patient-derived xenograft models: an emerging platform for translational cancer research. , 2014, Cancer discovery.
[28] A. Wotherspoon,et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial , 2013, The Lancet. Oncology.
[29] Galina Kurteva,et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. , 2013, The Lancet. Oncology.
[30] C. Klein,et al. Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker , 2012, Journal of Pharmacology and Experimental Therapeutics.
[31] J. Dick,et al. Human Solid Tumor Xenografts in Immunodeficient Mice Are Vulnerable to Lymphomagenesis Associated with Epstein-Barr Virus , 2012, PloS one.
[32] Aik Choon Tan,et al. Patient-derived tumour xenografts as models for oncology drug development , 2012, Nature Reviews Clinical Oncology.
[33] Davide Corà,et al. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. , 2011, Cancer discovery.
[34] M. Sliwkowski,et al. A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. , 2011, Cancer cell.
[35] Yoon-Koo Kang,et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.
[36] Joon-Oh Park,et al. Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial , 2019 .
[37] David R. Jones,et al. Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer. , 2018, Cancer discovery.
[38] Andrew Dunford,et al. Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma. , 2018, Cancer discovery.